Conference Home

Scientific Agenda

Accommodations & Travel

Sponsorship


OncologyEducation.com’s Best of ASCO® Conference is a program licensed by the American Society of Clinical Oncology and will be held on June 16, 2017 in Toronto, Ontario. The focus of this event will be to provide medical oncologists and other healthcare practitioners with a summary of the most significant treatment advances presented at the ASCO 2017 Annual Meeting, with presentations focused on several key disease sites. More details to come.
 

Meeting Objectives 

1. To summarize the most significant treatment advances presented at ASCO 2017

2. To review the current standard of care for key malignancies

3. To discuss the current controversies in the management of speci­fic cancers

Target Audience

Medical oncologists, pharmacists, nurses, and other oncology healthcare professionals.


Registration

Early bird rates - Deadline: Sunday May 21st
Physician Rate - $129.00
Nurses & Allied Health - $65.00

Standard rates
Physician Rate - $179.00
Nurses & Allied Health - $95.00

register


Program Chairs: 

Dr. Scott Berry, BSc, MD, MHSc, FRCPC

Dr. Berry is a medical oncologist at Sunnybrook Odette Cancer Centre and an Associate Professor in the Faculty of Medicine at the University of Toronto. He completed his general medical training and medical oncology training at the University of Toronto. Dr. Berry is an active participant in clinical research at the National Cancer Institute of Canada (NCIC) Clinical Trials Group and the North American Intergroup. He has been involved in important international trials in colorectal cancer that have been published in journals including the New England Journal of Medicine and the Annals of Oncology. Dr. Berry has also authored several prostate and colorectal cancer guidelines for the Cancer Care Ontario Program in Evidence Based Care and chaired national consensus guideline meetings for the Colorectal Cancer Association of Canada.

Dr. Berry also loves teaching and holds several leadership positions in education. He has won several teaching awards including the University of Toronto Division of Medical Oncology Education Award. He chairs the Royal College of Physicians and Surgeons of Canada Specialty Committee for Medical Oncology. He is the Program Director for the Medical Oncology Training Program at the University of Toronto and Co-Medical Director of www.OncologyEducation.com.

His other academic interests are the bioethical issues surrounding the care of people with cancer, in particular the ethical issues surrounding funding new and expensive cancer medications. Dr. Berry holds a master's degree in bioethics from the University of Toronto. He has also served on the ASCO Ethics Committee and is the ethics advisor to the pan-Canadian Oncology Drug Review and the NCIC Data Safety Monitoring Committee.

 

Dr. Natasha Leighl, MD, MMSc, FRCPC

Dr. Leighl is a professor in the Department of Medicine at the University of Toronto, Canada. She is also lung site lead in the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre/University Health Network, as well as the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development at Princess Margaret Cancer Foundation. She is co-chair of the Committee on Economic Analysis and on the Lung Site Executive of the Canadian Cancer Clinical Trials Group (formerly NCIC CTG).

Dr Leighl has authored or coauthored more than 100 articles published in such journals as the Journal of Clinical Oncology, Clinical Lung Cancer, The New England Journal of Medicine, and Cancer. She is co-editor of the Lung Section of the Oncologist, the Pharmacoeconomic Section of Current Oncology and is on the editorial board of the Journal of Thoracic Oncology (formerly Web Editor). She is also president of Lung Cancer Canada.  


Other Information

*This meeting has been approved by the American Society of Clinical Oncology. ASCO is not the CME provider for this activity.

**Best of ASCO® and any related logos are trademarks of the American Society of Clinical Oncology®.


Featured Oncology News

Powered by OBR Oncology